Table 3.
In-hospital outcomes of SGLT2-i users vs. non-SGLT2-i users.
| Total | SGLT2-i users | Non-SGLT2-i users | P -value | |
|---|---|---|---|---|
| (N = 646) | (N = 111) | (N = 535) | ||
| Hospital stay, days | 5 (4–8) | 5 (4–8) | 5 (4–8) | 0.526 |
| hs-TnI max | 2,368 (625–9,224) | 903 (278–2,438) | 3,155 (731–9,223) | <0.001 |
| HbA1c | 51 (45–59) | 52 (48–57) | 50 (44–60) | 0.137 |
| SD | 49.8 ±46.5 | 44.7 ±50.2 | 51 ±45.6 | 0.206 |
| CV | 0.27 ±0.19 | 0.25 ±0.20 | 0.27 ±0.19 | 0.234 |
| In-hospital glucose-lowering strategy | ||||
| Insulin s.c., n (%) | 430 (66.6) | 57 (51.4) | 394 (73.6) | <0.001 |
| Insulin i.v., n (%) | 65 (10.1) | 17 (15.3) | 144 (26.9) | 0.010 |
| In-hospital outcomes | ||||
| Arrhythmia, n (%) | 91 (14.1) | 7 (6.3) | 84 (15.7) | 0.010 |
| New-onset AF, n (%) | 56 (8.7) | 5 (4.5) | 51 (9.5) | |
| VT/VF, n (%) | 35 (5.4) | 2 (1.8) | 33 (6.2) | |
| Re-AMI, n (%) | 7 (1.1) | 1 (0.9) | 6 (1.1) | 0.838 |
| Re-PCI, n (%) | 13 (2.0) | 4 (3.6) | 9 (1.7) | 0.190 |
| IABP, n (%) | 23 (3.6) | 4 (3.6) | 19 (3.6) | 0.978 |
| CI-AKI, n (%) | 68 (10.5) | 6 (5.4) | 70 (13.1) | 0.022 |
Continuous variables are presented as mean±SD or as median (IQR); categorical variables as number (%). AF, Atrial Fibrillation; AMI, Acute Myocardial Infarction, CI-AKI, Contrast-Induced Acute Kidney Injury; Hs-TnI, high sensitivity Troponin I; IABP, Intra-Aortic Balloon Pump; i.v., intravenous; MACE, major adverse cardiovascular events; PCI, Primary Percutaneous Coronary Intervention; s.c., subcutaneous; VF, Ventricular Fibrillation; VT, Ventricular Tachycardia.